IHMA Publications & Posters

Poster Presentations by IHMA


  1. ACCP 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial activity Against Selected Species of Glucose Non-fermenting Organisms
  2. ACCP 2005: United States In Vitro AntibacterialActivity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  3. ACCP 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - United States In Vitro Antibacterial Activity against Selected Species of Enterococci
  4. ACCP 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  5. ASHP 2005: Acinetobacter Resistance In The United States: In Vitro Evaluation Of Tigecycline and Comparators Against Recent Isolates
  6. ASHP 2005: Determining Tigecycline in vitro Activity against Multi-Drug Resistant Enterobacteriaceae for the T.E.S.T. Program - United States Data
  7. ASHP 2005: Evaluating Antibiotic Cross-Resistance in Clinical Isolates of Enterobacteriaceae from the United States against 10 Antimicrobial Agents - The T.E.S.T. Program
  8. ASHP 2005: In vitro activity of Tigecycline against Multi-Drug Resistant Acinetobacter in the United States - T.E.S.T. Program 2004- 2005
  9. ASHP 2005: Tigecycline in vitro Activity against Staphylococcus aureus and Enterococcus strains Resistant To Other Drugs In The T.E.S.T. Program - United States, 2004 - 2005
  10. ASM 2000: A Global Comparative In Vitro Surveillance gender Study of Against 24,955 Isolates in Europe, Canada and the United States
  11. ASM 2000: Activity of Gemifloxacin (SB-265805) Against Penicillin-, Macrolide- and Ciprofloxacin-resistant Streptococcus pneumoniae Isolated in the United States, Canada and Europe
  12. ASM 2000: In Vitro Activity of Gemifloxacin Against Enterobacteriaceae Isolated in North America
  13. ASM 2001: Activity of Gatifloxacin Against Penicillin, Macrolide and Ciprofloxacin - Resistant S. pneumoniae Isolated from Pediatric, Adult and Elderly Hospitalized Patients in the US
  14. ASM 2001: Activity of Gatifloxacin Against P. aeruginosa and Enterobacteriacease Isolated from Hospitalized Patients in the US
  15. ASM 2001: Quinolone, Beta-lactam and Macrolide Activity Against S. pneumoniae from Hospitalized Patients in the United States Irrespective of Regional Resistance Patterns
  16. ASM 2001: In Vitro Activity of Gatifloxacin Against Respiratory Tract Pathogens from Hospitalized Patients Isolated in 108 Sites from the US
  17. ASM 2002: Activity of Respiratory Fluoroquinolones Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Against 4982 Upper and Lower Respiratory Tract Streptococcus pneumoniae (SP ) Isolates Recovered From 124 Sites in the United States
  18. ASM 2002: Determination of Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Resistant Streptococcus pneumoniae (SP ) Isolates from Respiratory and Blood Sources in a Multi-center In Vitro Evaluation
  19. ASM 2002: A Recent Evaluation of In Vitro Activity of Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Against 2517 Streptococcus pneumoniae (SP ) Isolates Recovered From Sterile Body Sites
  20. ASM 2003: Global Survey of In Vitro Antimicrobial Suscepti bilities of Bacteroides, Prevotella, Fusobacterium, Clostridium, Eubacterium, and Peptostreptococcus Species
  21. ASM 2003: Comparison of Etest and Agar Dilution for the Susceptibility Testing of 933 Anaerobic Isolates
  22. ASM 2003: A Multi-National In Vitro Surveillance of ESBL Producers, VREF and MRSA. Results of the Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) Study: 2001 – 2002
  23. ASM 2004: Comparison In Vitro Activity of Garenoxacin Against 618 Clinical Aerobes and Anaerobes Isolated from Clinical Gynecological Infections
  24. ASM 2004: Piperacillin/tazobactam MIC and Disk Correlation Study for ESBL and Non-ESBL Producing Organisms Using NCCLS Published Guidelines versus Proposed Breakpoints
  25. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  26. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Selected Species of Enterococcus spp. - North America Data, 2004
  27. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against Selected Species of Non-Glucose Fermenting Gram-negative Rods - United States Data, 2004
  28. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 14,705 Gram-positive and Gram-negative Pathogens
  29. ASM 2006: An In Vitro Evaluation of Tigecycline and Ten Comparators against Methicillin-Resistant Staphylococcus Aureus Collected From a Recent Global Population: TEST Program 2006
  30. ECCMID 2000: Gemifloxacin Demonstrates Potent In Vitro Activity Against Global Isolates of Antibiotic-resistant Streptococcus pneumoniae
  31. ECCMID 2002: A 2001 Multi-Center, Multi-Country Surveillance Study Identifying Antibiotic Resistance To Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium and Methicillin Resistant Staphylococcus Aureus Isolates
  32. ECCMID 2003: Accuracy in determining telithromycin MIC values against Streptococcus pneumoniae
  33. ECCMID 2005: A comparative in vitro analysis of amoxicillin-clavulanic acid and seven comparative agents in 15,499 peadiatric respiratory isolates
  34. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Enterobacteriaceae
  35. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  36. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - European In Vitro Antibacterial Activity against Selected Species of Enterococci
  37. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Enterococci
  38. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - European In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae
  39. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - United States In Vitro Antibacterial Activity against Selected Species of Enterococci
  40. ECCMID 2005: Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen-Reducing Agent May Be Required in The Absence of Fresh Media
  41. ECCMID 2005: European In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  42. ECCMID 2005: Global In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  43. ECCMID 2005: United States In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  44. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - European In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms
  45. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms
  46. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial activity Against Selected Species of Glucose Non-fermenting Organisms
  47. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against Gram-positive and Gram-negative Pathogens in Asia
  48. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 3,686 Gram-positive and Gram-negative Pathogens in Europe
  49. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  50. ECCMID 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 13,669 Gram-positive and Gram-negative Pathogens
  51. ECCMID 2006: Tigecycline In Vitro Activity in an Out-patient vs. In-patient Global Population
  52. ECCMID 2006: In Vitro Activity of Tigecycline and Comparators against Community and Hospital Acquired Infections In The United States - T.E.S.T. Program 2006
  53. ECCMID 2006: Tigecycline In Vitro Activity against In-patient and Out-patient Pathogens Collected From Centers In Europe - T.E.S.T. Program 2006
  54. ECCMID 2006: Asia and Pacific Rim Community vs. Hospital Acquired Infections - In vitro Activity Against Tigecycline and Comparators
  55. ECCMID 2006: The In Vitro Activity of Tigecycline and 10 Comparators in a Global Population - T.E.S.T. Program 2006
  56. ECCMID 2006: Tigecycline Antibacterial Activity in Current (2004-06) United States Pathogen Population
  57. ECCMID 2006: Tigecycline In Vitro Activity in Current European Pathogens - T.E.S.T. Program 2006
  58. ECCMID 2006: Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae Evaluated In Vitro Against Tigecycline and Comparator Agents - T.E.S.T. Program 2006
  59. ECCMID 2006: Tigecycline In Vitro Activity Against Often Difficult To Treat Pathogens From Centers In Asia/Pacific Rim - T.E.S.T. Program 2006
  60. ECCMID 2006: Tigecycline In Vitro Evaluation of 1,145 Methicillin-Resistant Staphylococcus Aureus
  61. ECCMID 2006: In Vitro Evaluation of Tigecycline Against 288 Recent Isolates of Vancomycin-Resistant Enterococci (VRE) - T.E.S.T. Program 2006
  62. ECCMID 2006: Evaluating Tigecycline Against Cross Resistant Enterobacteriaceae in the Global T.E.S.T. Program
  63. ECCMID 2006: Acinetobacter Resistance In Clinical Isolates from The United States Evaluated against Tigecycline and 10 Comparators
  64. ECCMID 2006: Cross-Resistance in Clinical Isolates of Enterobacteriaceae from the United States Evaluated against Tigecycline and 10 Comparator Antimicrobial Agents
  65. ECCMID 2006: Evaluating Cross Resistance for Enterobacteriaceae as Compared to Tigecycline For the T.E.S.T. Program in Europe
  66. ECCMID 2006: Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs Evaluated against Tigecycline- T.E.S.T. Program Global Data
  67. ECCMID 2006: Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs Evaluated against Tigecycline- T.E.S.T. Program Global Data
  68. ECCMID 2006: Antibiotic Cross Resistance for Staphylococcus aureus and Enterococcus spp Among Tigecycline and 10 Comparator
  69. ECCMID 2006: Multi-Drug Resistant Acinetobacter in the United States Evaluated against Tigecycline - T.E.S.T. Program 2006
  70. ECCMID 2006: In Vitro Activity of Multi-Drug Resistant Acinetobacter against Tigecycline from the T.E.S.T. Program in Europe
  71. ECCMID 2006: Determining Tigecycline\'s in vitro Activity Multi-Drug Resistant Enterobacteriaceae from the T.E.S.T. Program - Global Data
  72. ECCMID 2006: In Vitro Activity Tigecycline and 10 Broad Spectrum Comparators against Multi-Drug Resistant Staphylococcus aureus: A Multi-nation Evaluation
  73. ECCMID 2006: Tigecycline In Vitro Activity Against Multi-Drug Resistant Acinetobacter spp. In The T.E.S.T. Program Global Data
  74. ECCMID 2007: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus species - Global Data, 2004 - 2006
  75. ECCMID 2007: Evaluation of In Vitro Activity of Tigecycline and Ten Comparators Against Methicillin-Resistant Staphylococcus aureus from 38 Countries: TEST Program 2004 - 2006
  76. ECCMID 2007: Comparison of In Vitro Activity of Tigecycline against Pathogens from Intensive Care Patients in Europe - T.E.S.T. Program 2006
  77. ECCMID 2007: Tigecycline In Vitro Activity Against Often Difficult to Treat European Pathogens
  78. ECCMID 2007: Variable Resistance Patterns among Tigecycline and 10 Comparators against Multi-Drug Resistant Acinetobacter from the T.E.S.T.
  79. ECCMID 2007: Patterns of Susceptibility of Gram-negatives/positives Isolated in the United Kingdom and Ireland
  80. ECCMID 2007: Changes in United States Regional Variations in Penicillin Resistant Rates of Streptococcus pneumoniae, 1999 to 2006
  81. ECCMID 2007: Antimicrobial Susceptibility of 2,537 Bacteremia Causative Pathogens: Tigecycline Evaluation Surveillance Trial (TEST) in Europe 2004-2006
  82. ECCMID 2007: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial Activity Against Selected Species of Enterococcus spp.
  83. ECCMID 2007: Impact of Different FDA and EU Breakpoints on Bacterial Susceptibility Patterns - Analysis of Data from the T.E.S.T Program
  84. ECCMID 2007: In Vitro Activity of Tigecycline Against Pathogens Isolated from Cerebrospinal Fluid - T.E.S.T. Program 2006
  85. ECCMID 2007: Antibacterial Activity of Tigecycline Against H. influenzae and S. pneumoniae (2004-06) Global Population - T.E.S.T. Program 2006
  86. ECCMID 2008: In Vitro Activity of Tigecycline and 13 Comparators against Pathogens from a Global Population of Intensive Care Patients in 2007
  87. ECCMID 2008: In Vitro Activity of Tigecycline Against In-patient and Out-Patient Isolates from a European Population
  88. ECCMID 2008: Comparative Analysis of Tigecycline in South America from 2004-2007
  89. ICAAC 2000: Quinolone resistance in Streptococcus pneumoniae evaluated in three Asian countries during 2003-2004
  90. ICAAC 2000: Gemifloxacin Comparative In Vitro Surveillance Study of Penicillin- and Macrolide-resistant Pneumococci and other Respiratory Pathogens in Asian and Pacific Rim Countries
  91. ICAAC 2000: Gemifloxacin Comparative In Vitro Surveillance Study of Penicillin- and Macrolide-resistant Pneumococci and other Respiratory Pathogens in Asian and Pacific Rim Countries
  92. ICAAC 2000: Global Resistance Patterns of Quinolones, Macrolides and b-Lactams From a Multi-center, Multi-country Study of >40,000 Isolates: The Gemifloxacin Surveillance Study
  93. ICAAC 2000: In Vitro Activity of Gemifloxacin Against Multiple-drug-resistant Strains of Streptococcus pneumoniae Isolated From 42 Countries in North America, Latin America, Europe, Asia, South Pacific and Africa/Middle East
  94. ICAAC 2002: Regional Incidence of Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin
  95. ICAAC 2003: Comparison InVitro Activity of Garenoxacin (BMS-284756) Against 706 Clinical Aerobes Isolated From Complicated Skin and Skin Structure Infections
  96. ICAAC 2003: In Vitro Activity of Garenoxacin (BMS-284756) Against 465 of Clinical Anaerobes Isolated From Intra-abdominal Infections
  97. ICAAC 2003: In Vitro Antibacterial Activity of Tigecycline, a Novel Glycylcycline, Against Clinical Isolates of Enterobacteriaceae
  98. ICAAC 2003: Tigecycline, a Novel Glycylcycline with Promising Anti-Staphylococcal Activity
  99. ICAAC 2003: In Vitro Study of Tigecycline Against 776 Clinical Isolates of Non-
  100. ICAAC 2004: THE EFFECTS OF CO2 ON THE IN VITRO ACTIVITY OF TELITHROMYCIN WHEN USING ETEST® COMPARED WITH BROTH MICRODILUTION IN 7 REFERENCE LABORATORIES
  101. ICAAC 2004: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates
  102. ICAAC 2004: In Vitro Antibacterial Activity of Tigecycline Against Isolates of Vancomycin-Resistant and -Sensitive Enterococcus faecium from the Tigecycline Evaluation Surveillance Trial (TEST)
  103. ICAAC 2004: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In vitro Antibacterial Activity Against Fastidious Isolates
  104. ICAAC 2004: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae
  105. ICAAC 2004: Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen-Reducing Agent May Be Required in The Absence of Fresh Media
  106. ICAAC 2005: Retapamulin (SB-275833), A Novel Topical Pleuromutilin, Is Active Against Community Associated Methicillin and Mupirocin-Resistant S. aureus Isolates From Uncomplicated Skin And Skin Structure Infections (SSSIs)
  107. ICAAC 2005: Retapamulin (SB-275833), a Novel Pleuromutilin – a Multi-center Global Surveillance of Activity Against 3,797 Beta and Alpha Hemolytic Streptococci Isolated from Skin and Skin Structure Infections (SSSIs)
  108. ICAAC 2005: In Vitro Activity of Retapamulin (SB-275833), a Novel Topical Antimicrobial, against 3721 Gram-Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) From 17 Sites in North America
  109. ICAAC 2005: A Multi-center Global Surveillance Study of the In Vitro Activity of Retapamulin (SB-275833), A Novel Topical Pleuromutilin Against 2950 Clinical Isolates of S. aureus and Coagulase Negative Staphylococci from Uncomplicated Skin
  110. ICAAC 2005: Tigecycline in vitro Activity against a Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs in the T.E.S.T. Program Worldwide
  111. ICAAC 2005: Tigecycline in vitro Activity against Staphylococcus aureus and Enterococcus strains Resistant To Other Drugs In The T.E.S.T. Program - United States, 2004 - 2005
  112. ICAAC 2005: Tigecycline Antibacterial Activity in Current (2004-05) U.S. Pathogen Population
  113. ICAAC 2005: Recently Collected Extended Spectrum Beta-Lactamase (ESBL) Isolates (354) Evaluated In Vitro Against Tigecycline and Comparator Agents: Global Perspective
  114. ICAAC 2005: Methicillin-Resistant Staphylococcus Aureus (1,030) Collected From a Recent Global Population: Tigecycline In Vitro Evaluation
  115. ICAAC 2005: Vancomycin Resistant Enterococci (VRE) - A Global Problem: Evaluation of Tigecycline Against Recent Isolates From Multi-Centers Globally
  116. ICAAC 2005: In vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter from the T.E.S.T. Program Worldwide
  117. ICAAC 2005: An In Vitro Evaluation Of Tigecycline In An In-Patient vs. Out-Patient Population Worldwide
  118. ICAAC 2005: In-Patient vs. Out-Patient In Vitro Evaluation Of Pathogens Collected From Centers In Europe
  119. ICAAC 2005: T.E.S.T.: Validating the Activity of Tigecycline in Current European Pathogens
  120. ICAAC 2005: Evaluation of Tigecycline Against Often Difficult to Treat Pathogens From Centers in Asia/Pacific Rim
  121. ICAAC 2005: Multi Drug Resistant (MDR) S. aureus Are Susceptible to Tigecycline: T.E.S.T Program - United States Surveillance
  122. ICAAC 2005: The T.E.S.T. Program - Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators in a Global Population
  123. ICAAC 2006: In Vitro Activity of Tigecycline Against Pathogens From France – T.E.S.T. Program 2006
  124. ICAAC 2006: Spectrum and potency of tigecycline and comparators against nosocomial pathogens in Italy
  125. ICAAC 2006: In vitro Activity of Tigecycline and Commonly-Used Antimicrobials Against 549 Isolates Collected From 2004 to 2006 in Belgium
  126. ICAAC 2006: In Vitro Activity of Tigecycline Against Pathogens From Switzerland, Sweden, and The Netherlands - T.E.S.T. Program 2006
  127. ICAAC 2006: Susceptibility of Tigecycline and Comparators in Nosocomial Pathogens from South America Hospitals: T.E.S.T. program 2004-2006
  128. ICAAC 2006: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the years 2004 to 2006 - Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  129. ICAAC 2006: Tigecycline Antibacterial Activity in Current (2004-06) Global Population - An Age Population Analysis - T.E.S.T. Program 2006
  130. ICAAC 2007: Changes of Susceptibility Patterns for Tigecycline and Comparators in Western Europe from 2004-2006
  131. ICAAC 2007: Determining In Vitro Activity of 14 Antimicrobials in Asia/Pacific Rim from 2004-2006
  132. ICAAC 2007: Evaluating Multidrug Resistant (MDR) Acinetobacter Isolates from Latin American Countries: The T.E.S.T. Program
  133. ICAAC 2007: A Comparative Study of 14 Antimicrobials Against Vancomycin Resistant Enterococci (VRE) in Central and South America
  134. ICAAC 2007: An Age Analysis of Gram-positive and Gram-negative Isolates from Centers in the Middle East: The T.E.S.T. Program
  135. ICAAC 2007: The Activity of Tigecycline and Comparators to Pathogens by Body Sites Collected in the U.S. (2004-2007)
  136. ICAAC 2007: A Comparison of the Efficacy of Tigecycline from University Hospitals in Europe and the United States
  137. ICAAC 2007: Susceptibility Patterns of Tigecycline and Comparators in Latin America from Hospitals of Various Bed Sizes
  138. ICAAC 2007: The carbapenem PZ-601 (SMP-601) has potent in vitro Gram-positive, Gram-negative and anaerobic bacterial activity.
  139. ICC 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Gram-positive and Gram-negative Pathogens in Asia and Pacific Rim
  140. ICC 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 3,935 Gram-positive and Gram-negative Pathogens in Europe
  141. ICC 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 14,706 Gram-positive and Gram-negative Pathogens
  142. ICC 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,567 Gram-positive and Gram-negative Pathogens in the United States
  143. ICID 2002: Incidence Of Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae (ESBL), Vancomycin Resistant Enterococcus Faecium (VREF) And Methicillin Resistant Staphylococcus Aureus (MRSA) In France Through the Pan-European Antimicrobial Resistance Using Lo
  144. ICID 2002: Checking For Incidence of Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF) and Methicillin Resistant Staphylococcus Aureus (MRSA) in 26 Centers from 12 European Countries: The Pan-Europ
  145. ICID 2002: Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF) and Methicillin Resistant Staphylococcus Aureus (MRSA): Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) - A 2001
  146. ICID 2004: Tigecycline in vitro antibacterial activity against 249 methicillin resistant and 250 methicillin sensitive staphylococcus aureus isolates
  147. ICID 2004: Tigecycline In Vitro Antibacterial Activity Against 1,499 Isolates of Enterobacteriaceae
  148. ICID 2004: Tigecycline In Vitro Antibacterial Activity Against 249 Methicillin Resistant and 250 Methicillin Sensitive Staphylococcus aureus Isolates
  149. ICID 2004: Tigecycline In Vitro Antibacterial Activity Against Isolates of Non-Enterobacteriaceae
  150. ICID 2008: Bacterial Resistance Patterns of Isolates from Various Body Sites: The European T.E.S.T. Program
  151. ICID 2008: Evaluation of 11 Antimicrobial Agents Against Australian Bacteremia Isolates: The T.E.S.T. Program
  152. ICID 2008: Efficacy of Tigecycline Against Worldwide Levofloxacin-Resistant Pathogens
  153. ICID 2008: Analysis of Tigecycline Activity Against Pathogens Isolated from Lower Respiratory Infections – The Global T.E.S.T. Program 2007
  154. ICID 2008: Comparison of In Vitro Activity of Tigecycline Against Vancomycin Resistant Enterococci (VRE) in the U.S. Analyzed by CDC Regions
  155. ICID 2008: A Profile of Tigecycline Activity Against Clinical Isolates in Spain and Portugal 2004 – 2007
  156. ICMS 2006: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Gram-Negative Clinical Pathogens from Asia and the Pacific Rim
  157. ICMS 2006: Tigecycline in vitro Activity against Gram-Positive Pathogens and Common Resistant Phenotypes from Asia and the Pacific Rim - The T.E.S.T. Program 2005
  158. ICMS 2006: The In-Vitro Antibacterial Activity of Tigecycline from an Asia/Pacific Rim Population - The T.E.S.T. Program 2005
  159. ICMS 2006: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity of Tigecycline at Flinders Medical Centre, South Australia
  160. ICMS 2006: Tigecycline In-Vitro Antibacterial Activity from a Global Perspective - The T.E.S.T. Program 2005
  161. ICMS 2007: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Australian Experience, 2006
  162. ICMS 2007: The In-Vitro Antibacterial Activity of Tigecycline from an Asia/Pacific Rim Population - The T.E.S.T. Program 2006
  163. ICMS 2007: A Presentation of Global Data from Tigecycline Evaluation Surveillance Trials (TEST) Program, 2004 - 2006
  164. IDSA 2005: A Global Surveillance Program to Determine the In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter spp.
  165. IDSA 2005: A Global Surveillance to Determine Tigecycline’s In Vitro Activity against Multiple Resistant Phenotypes of Enterobacteriaceae
  166. IDSA 2005: A Global Surveillance to Determine Tigecycline’s In Vitro Activity against Multiple Resistant Phenotypes of Enterobacteriaceae
  167. IDSA 2005: A Global Surveillance Program to Determine the In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter spp.
  168. IDSA 2005: Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators Worldwide
  169. IDSA 2005: Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators Worldwide
  170. IDSA 2005: Resistance Patterns of Methicillin- and Mupirocin-resistant S. aureus from Uncomplicated Skin and Skin Structure Infections (SSSIs) in the United States from March 2004–March 2005; Retapamulin Surveillance Study
  171. IDSA 2005: Gram Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) and Collected from Sites in the United States are Highly Susceptible to Retapamulin (SB275833), a Novel Topical Antimicrobial
  172. IDSA 2006: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Nosocomial Pathogens in South America, 2004-2006
  173. IDSA 2006: In Vitro Activity of Tigecycline Against 24,278 Pathogens Isolated from Common Body Sites and Tissues in North America
  174. IDSA 2007: A Global Evaluation of Methicillin-Resistant Staphylococcus aureus from the T.E.S.T. Program
  175. IDSA 2007: Changes in United States Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae, 1999 to 2006
  176. ISAAR 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae from the Pacific Rim
  177. ISAAR 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Selected Species of non-glucose fermenting Gram negative rods from Asia and the Pacific Rim
  178. ISAAR 2005: In Vitro Study to Determine the Activity of Tigecycline against Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  179. ISAAR 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Selected Enterococcus species from Asia and the Pacific Rim
  180. ISAAR 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Nosocomial and Community Pathogens from Asia and the Pacific Rim
  181. ISAAR 2005: In Vitro Antibacterial Activity of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  182. ISAAR 2007: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial
  183. ISAAR 2007: Susceptibilities of Hospital- and Community-Acquired Clinical Pathogens from Asian Hospitals: TEST Program in Asia 2006
  184. ISAAR 2007: Tigecycline and Comparator Agents In Vitro Activity Against Recently Collected Extended Spectrum Beta-Lactamase Isolates - TEST Program
  185. ISAAR 2007: In Vitro Activity of Tigecycline Against In-patient and Out-patient Enterobacteriaceae
  186. ISAAR 2007: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Current Isolates of Staphylococcus aureus and Enterococcus Species Resistant to Other Drugs - Worldwide Data, 2006
  187. ISAAR 2007: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program -In Vitro Antibacterial Activity Against Selected Gram-Negative Clinical Pathogens from Asia and the Pacific Rim
  188. ISAAR 2007: In Vitro Antibacterial Activity of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) in the USA
  189. ISAAR 2007: Evaluating Multi-Drug Resistant Acinetobacter in a Worldwide Study
  190. ISAAR 2007: Variability of Antimicrobial Susceptibility in Isolates from Patients in Different Age Groups in the USA: 2004-2006
  191. ISAAR 2007: Antimicrobial Susceptibility of Isolates Collected from Different Body Sites in Asia and the Pacific Rim: Tigecycline Evaluation Surveillance Trial (TEST)
  192. ISAAR 2007: Antibiotic Activity against Vancomycin Resistant Enterococci from the Tigecycline Evaluation Surveillance Trials (TEST) Program 2006
  193. ISAAR 2007: Tigecycline and Comparators Susceptibility Against Enterobacteriaceae of Various Resistant Phenotypes Globally
  194. ISAAR 2007: Comparison of Antimicrobial Susceptibility of Isolates from Various Body Sites: Western European Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  195. ISAAR 2007: Out-patient vs. In-patient Isolates from an Eastern European Population: 2004-2006 T.E.S.T.
  196. ISAAR 2007: Global Study to Determine Antibacterial Activity of Tigecycline and Comparators Against H. influenzae and S. pneumoniae from 2004-2006
  197. ISAAR 2007: In Vitro Activity of Tigecycline and Comparators Against Difficult-to-Treat European Isolates
  198. ISAAR 2007: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the years 2004 to 2006 -Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  199. ISAAR 2007: Activity of Tigecycline Against Antibiotic Resistant Clinical Isolates of Enterobacteriaceae from the United States - The T.E.S.T. Program
  200. ISAAR 2007: Antimicrobial Susceptibility of 2,537 Bacteremia Causative Pathogens: Tigecycline Evaluation Surveillance Trial (TEST) in Europe 2004-2006
  201. ISAAR 2007: Antimicrobial Activity of Tigecycline and Comparators from Inpatient and Outpatient Pathogens in North America
  202. SHEA 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  203. SHEA 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  204. SHEA 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  205. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Methicillin Resistant and Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  206. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Vancomycin Resistant and Sensitive Enterococcus faecium Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  207. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Species of Enterobacteriaceae from the Tigecycline Evaluation Surveillance Trial (T.E.S.T)
  208. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  209. WestPac 2006: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  210. WestPac 2006: In Vitro Activity of Tigecycline and Commonly-Used Antimicrobials Against 1,559 Isolates Collected from 2004 to 2006 in Spain and Portugal
  211. WestPac 2006: Activity of Tigecycline and Comparators in Nosocomial Pathogens from Italy
  212. WestPac 2006: Bacterial pathogens in hospitalized patients in Germany: Susceptibility patterns from the TEST study
  213. WestPac 2006: Changes in United States Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae, 1999 to 2006
  214. WestPac 2006: Antimicrobial Susceptibility Of Nosocomial Pathogens in South America - Results From the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) 2004-2006
  215. WestPac 2006: In Vitro Evaluation of Tigecycline and Comparators from 2004 to 2006 - A Global Study
  216. WestPac 2006: Comparison of Antimicrobial Susceptibility of Isolates from Various Body Sites: Western European Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  217. WestPac 2006: In Vitro Activity of Tigecycline Against In-patient and Out-patient Enterobacteriaceae Collected from Australia - T.E.S.T. Program 2006
  218. WestPac 2006: Evaluation of Tigecycline and Comparators in Nosocomial Pathogens from South America
  219. WestPac 2006: Tigecycline vs. Comparators Against Multidrug Resistant Pathogens in Turkey in 2006
  220. WestPac 2006: Global Evaluation of Tigecycline and Comparators from 2004 to 2006 - Analyzed by Age
  221. WestPac 2006: Age-Related Variances in Pathogen Susceptibilities in the USA (2004-2006): Results from the TEST Study
  222. WestPac 2006: Tigecycline Antibacterial Activity in Current (2004-06) Western European Population - An Age Population Analysis - T.E.S.T. Program 2006
  223. WestPac 2006: Comparison of Antimicrobial Susceptibility of Isolates From Various Body Sites: Asia/Pacific Results From the Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  224. WestPac 2006: Susceptibility to Tigecycline of 23,125 Pathogens Isolated from Common Body Sites and Tissues in North America
  225. WestPac 2006: In vitro activity of Tigecycline Against Global Isolates of Multidrug Resistant Acinetobacter Species
  226. WestPac 2006: Tigecycline is active against Eastern European in-patient and out-patient clinical isolates
  227. WestPac 2006: In Vitro Activity of Tigecycline Against South African Blood, Respiratory Tract, and Urinary Tract Isolates - T.E.S.T. Program 2006
  228. WestPac 2006: In Vitro Activity of Tigecycline Against Pathogens Isolated from Most Common Body Sites - Eastern European Data - T.E.S.T. Program 2006
  229. WestPac 2006: Comparison of Antimicrobial Susceptibility of 1,267 Isolates from Various Body Sites: South American Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  230. WestPac 2006: Tigecycline’s In Vitro Activity vs. Isolates from Intensive Care and Non-Intensive Care Patients - Western Europe T.E.S.T. Program 2006
  231. WestPac 2006: North American inpatient and outpatient pathogens: Monitoring resistance in the TEST study
  232. WestPac 2006: Susceptibilities of hospital- and community-acquired pathogens in Asia in 2006
  233. WestPac 2006: Gender Analysis of Global Pathogen Susceptibility (2004-2006): Tigecycline vs. Comparators in the TEST Study
  234. WestPac 2006: Tigecycline is Active Against Global Isolates of S. pneumoniae and H. influenzae: Results from the TEST Program in 2006
  235. WestPac 2006: In vitro Activity of Tigecycline and Comparators in Belgium from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
  236. WestPac 2006: In Vitro Activity of Tigecycline and Comparators Against Pathogens from Switzerland, Sweden and The Netherlands
  237. WestPac 2006: In Vitro Activity of Tigecycline against In-patient and Out-patient Pathogens Collected From Centers in Pacific Rim Countries - T.E.S.T. Program 2006
  238. WestPac 2006: Patterns of susceptibility of gram negatives/positives isolated in the United Kingdom and Ireland